BUZZ-Belite Bio eyes fresh record after $350 mln equity raise
I'm PortAI, I can summarize articles.
Belite Bioshares rose 3.9% premarket to $160 after a $350 million equity raise. The company sold ~2.3 million American Depositary Shares at $154. The proceeds will be used for commercialization, pipeline development, and general purposes. Mizuho upgraded BLTE to 'outperform' with a price target of $194. All six brokerages covering BLTE are bullish, with a median price target of $140. BLTE shares have surged 144% over the past three months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments